Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Analysts

Posted by on Aug 2nd, 2026

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $38.0833.

A number of analysts have weighed in on JANX shares. Truist Financial reiterated a “buy” rating and issued a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. Piper Sandler reduced their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. JonesTrading lowered their target price on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. Finally, UBS Group lowered shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $57.00 to $15.00 in a report on Wednesday, April 15th.

Check Out Our Latest Stock Report on Janux Therapeutics

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, VP Maria Dobek sold 2,038 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the sale, the vice president directly owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. This represents a 5.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider directly owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp lifted its position in Janux Therapeutics by 103.8% during the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after buying an additional 1,962,486 shares in the last quarter. Prosight Management LP grew its holdings in Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after acquiring an additional 1,527,173 shares during the last quarter. Wellington Management Group LLP increased its position in Janux Therapeutics by 129.5% in the 4th quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company’s stock valued at $22,221,000 after acquiring an additional 908,582 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in Janux Therapeutics in the 4th quarter valued at about $12,221,000. Finally, Alyeska Investment Group L.P. raised its stake in shares of Janux Therapeutics by 206.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,301,089 shares of the company’s stock worth $17,955,000 after acquiring an additional 876,244 shares during the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Stock Down 2.6%

NASDAQ:JANX opened at $15.17 on Friday. Janux Therapeutics has a 12-month low of $12.12 and a 12-month high of $35.34. The firm has a market capitalization of $925.07 million, a PE ratio of -8.24 and a beta of 2.52. The firm has a 50-day moving average price of $14.91 and a 200 day moving average price of $14.38.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million. On average, research analysts expect that Janux Therapeutics will post -1.7 EPS for the current year.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

Featured Stories

Analyst Recommendations for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.